2016 Press Releases


Keyword Search
2017 | 2016 | 2015 | 2014
DateTitle 
12/13/16Tocagen Expands Toca 5, Phase 2/3 Clinical Trial for Recurrent Brain Cancer, to Israel
Patient Enrollment in the United States and Canada OngoingSAN DIEGO – Dec. 13, 2016 — Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced its randomized, controlled Phase 2/3 clinical trial, called Toca 5, is now enrolling patients in Israel. Enrollment in the trial is ongoing in the United States and Canada. The study compares a cancer-selective virus, Toca 511 (vocimagene amiretrorepvec), in combination with Toca FC (extended-release 5-fluorocytosine) to stan... 
Printer Friendly Version
11/21/16Tocagen Presents Updated Clinical and Preclinical Data at Scientific Meetings
SCOTTSDALE, Ariz. – Nov. 21, 2016 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced updated interim data from ongoing Phase 1 and preclinical studies of Toca 511 (vocimagene amiretrorepvec) in combination with Toca FC (extended-release 5-fluorocytosine) were presented at the 21st Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), the 2nd CNS Anticancer Drug Discovery and Development Conference and the Society for Immunother... 
Printer Friendly Version
11/10/16Tocagen to Present Clinical and Preclinical Data at Upcoming Scientific Meetings
SAN DIEGO – Nov. 10, 2016 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced updated data from the company's clinical and preclinical studies of Toca 511 and Toca FC in high grade glioma will be highlighted in oral and poster presentations at the 21st Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), the 2nd CNS Anticancer Drug Discovery And Development Conference and the Society for Immunotherapy of Cancer (SITC) 31st Annu... 
Printer Friendly Version
11/02/16Tocagen Strengthens Leadership Team: Martin Duvall Appointed as Chief Executive Officer
SAN DIEGO, Nov. 2, 2016 — Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced the appointment of Martin "Marty" Duvall as chief executive officer and member of the company's board of directors. Harry Gruber, M.D., who previously served as Tocagen's chief executive officer, has assumed the role of president, research and development, and will remain a member of Tocagen's board of directors."Marty has clearly demonstrated over his career that he is skil... 
Printer Friendly Version
10/05/16Tocagen Presents Updated Tumor Response Data for its Cancer-Selective Gene Therapy
VANCOUVER, Canada – October 5, 2016 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced updated clinical data for Toca 511 (vocimagene amiretrorepvec) in combination with Toca FC (extended-release 5-fluorocytosine) for the treatment of recurrent high grade glioma.The new data were presented at the 10th International Oncolytic Virus Meeting in Vancouver, Canada by Douglas J. Jolly, Ph.D., executive vice president of research and pharmaceutical development at T... 
Printer Friendly Version
09/30/16Tocagen to Present Clinical and Preclinical Data at Two Scientific Meetings
SAN DIEGO – September 30, 2016 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced clinical and preclinical data involving Toca 511 & Toca FC for the treatment of recurrent high grade glioma will be presented at the 10th International Oncolytic Virus Meeting, to be held Oct. 1-4 in Vancouver, Canada and the European Society of Gene & Cell Therapy Annual Meeting, to be held Oct. 12-21 in Florence, Italy.Details of the International Oncolytic Virus Meet... 
Printer Friendly Version
09/22/16First Patient Enrolled in Toca 6, Tocagen’s Trial for Metastatic Cancers Evaluating Intravenously Delivered Toca 511 Virus
Study Investigates Potential Expansion Indications for Toca 511 & Toca FCSAN DIEGO – Sept. 22, 2016 – Tocagen, Inc., a clinical-stage, cancer-selective immunotherapy company, today announced the first patient has been enrolled in Toca 6, a Phase 1b study evaluating intravenously delivered Toca 511 (vocimagene amiretrorepvec) in combination with Toca FC (extended-release 5-fluorocytosine) in patients with metastatic cancers. The study is planned to include patients with colorectal cancer wi... 
Printer Friendly Version
07/06/16RiboMed and Tocagen Announce Collaboration to Analyze Epigenetic Prognostic Markers
SAN DIEGO – July 6, 2016 – RiboMed Biotechnologies, Inc. and Tocagen Inc., today announced a collaboration to analyze potential epigenetic prognostic and predictive markers, including the gene for the DNA repair enzyme O-6-Methylguanine-DNA Methyltransferase (MGMT), in Tocagen's clinical trials evaluating the investigational treatment Toca 511 & Toca FC in patients with recurrent high grade gliomas (HGGs).HGGs, including glioblastoma, are the most aggressive primary malignant brain tumors an... 
Printer Friendly Version
06/01/16Study Published in Science Translational Medicine Reports Favorable Safety and Extended Survival for Brain Cancer Patients Treated with Tocagen’s Cancer-Selective Viral Gene Therapy
SAN DIEGO – June 1, 2016 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced results from a multi-center study of an investigational immunotherapy, Toca 511 & Toca FC, have been published in the June 1, 2016, issue of Science Translational Medicine. The study, conducted in patients with recurrent brain cancer, showed extended survival compared to an external control, complete and partial tumor shrinkage determined by independent radiology review and favor... 
Printer Friendly Version
05/26/16Tocagen Announces Presentations at the 2016 BIO International Convention and Boston CEO Conference
SAN DIEGO – May 26, 2016 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced members of the company's management team will participate on a panel discussing the intersection of immuno, viral and gene-based therapies for cancer treatment and present a corporate overview at the 2016 BIO International Convention, to be held June 6-9 in San Francisco.In addition, Tocagen will participate in a panel discussion at the Boston CEO Conference, to be held May 31-June 1... 
Printer Friendly Version
05/13/16Tocagen to Present Clinical and Preclinical Data at Three Scientific Meetings
SAN DIEGO – May 13, 2016 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced that results from the clinical investigation of Toca 511 & Toca FC for the treatment of recurrent high grade glioma will be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 3-7 in Chicago, and the 17th Biennial Canadian Neuro-Oncology (CNO) Meeting, to be held June 9-11 in Toronto.In addition, preclinical data demonstrating that T... 
Printer Friendly Version
05/03/16Tocagen Presents Intravenous Toca 511 Clinical Data at the 84th AANS Annual Scientific Meeting
Encouraging Survival, Proof of Mechanism, and Favorable Safety Was DemonstratedCHICAGO – May 3, 2016 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced positive clinical data involving intravenously delivered Toca 511 (vocimagene amiretrorepvec) in combination with Toca FC (extended-release flucytosine) for the treatment of recurrent high grade glioma were presented at the 84th American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in... 
Printer Friendly Version
04/19/16Tocagen Presents Positive Preclinical, Proof-of-Mechanism Data at the American Association for Cancer Research (AACR) Annual Meeting
Combining Toca 511 and 5-FC with Checkpoint Inhibitors Reduces Tumor Burden in Preclinical ModelToca 511 and 5-FC Increased Survival in Preclinical Metastatic Colorectal Cancer ModelNEW ORLEANS – April 19, 2016 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced positive preclinical, proof-of-mechanism data involving Toca 511 and 5-fluorocytosine (5-FC) were presented at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans. The da... 
Printer Friendly Version
04/13/16Tocagen to Present Data from Clinical Trials and Preclinical Programs at Four Scientific Conferences
SAN DIEGO – April 13, 2016 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced that new results from the clinical investigation of Toca 511 (vocimagene amiretrorepvec) & Toca FC (extended-release 5-fluorocytosine) for the treatment of recurrent high grade glioma will be presented at the 84th American Association of Neurological Surgeons (AANS) Annual Scientific Meeting, to be held April 30-May 4 in Chicago.In addition, preclinical data supporting the... 
Printer Friendly Version
03/17/16Tocagen to Present at Three Oncology Conferences
SAN DIEGO – March 17, 2016 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced that members of the management team will present at the 9th Annual Oncology Commercialization & Market Access meeting, to be held March 22-23 in San Francisco; participate in a panel discussion at the Cancer Advance Boston conference, to be held April 4-5 in Boston; and present at the Phacilitate Oncology Leaders Forum, to be held April 5-6 in Boston.Details of the presentation... 
Printer Friendly Version
03/08/16Tocagen Expands Toca 5, Phase 2/3 Clinical Trial for Recurrent Brain Cancer to Canada
Patient Enrollment in the United States OngoingSAN DIEGO – March 8, 2016 — Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced that its randomized, controlled Phase 2/3 clinical trial, called Toca 5, has expanded internationally and is now enrolling patients in Canada. The company previously announced in December 2015 that the first patient had been enrolled in the Toca 5 trial in the United States. The study compares the combination of Toca 511 (vocimagene ami... 
Printer Friendly Version
02/16/16Tocagen Appoints John Wood as Vice President, Regulatory Affairs and Quality Assurance
SAN DIEGO – Feb. 16, 2016 — Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced that John Wood has been named vice president of regulatory affairs and quality assurance. Mr. Wood holds more than 20 years of regulatory affairs experience focusing on first-in-class drugs for diseases with high unmet need. While at IDEC Pharmaceuticals he played a leading role, in close collaboration with Genentech, in the first regulatory approval of RITUXAN® for the treatment of... 
Printer Friendly Version